Symbols / ABBV Stock $201.81 +0.66% AbbVie Inc.
ABBV (Stock) Chart
About
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Stock Fundamentals
Scroll to Statements| Market Cap | 356.95B | Enterprise Value | 417.70B | Income | 4.19B | Sales | 61.16B | Book/sh | -1.85 | Cash/sh | 2.97 |
| Dividend Yield | 3.45% | Payout | 276.79% | Employees | 57000 | IPO | — | P/E | 85.15 | Forward P/E | 12.55 |
| PEG | 0.47 | P/S | 5.84 | P/B | -109.09 | P/C | — | EV/EBITDA | 14.28 | EV/Sales | 6.83 |
| Quick Ratio | 0.41 | Current Ratio | 0.67 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | 2.37 | EPS next Y | 16.09 |
| EPS Growth | — | Revenue Growth | 10.00% | Earnings | 2026-04-29 | ROA | 9.81% | ROE | 62.25% | ROIC | — |
| Gross Margin | 71.62% | Oper. Margin | 34.11% | Profit Margin | 6.91% | Shs Outstand | 1.77B | Shs Float | 1.77B | Short Float | 1.27% |
| Short Ratio | 2.67 | Short Interest | — | 52W High | 244.81 | 52W Low | 176.11 | Beta | 0.36 | Avg Volume | 7.05M |
| Volume | 453.95K | Target Price | $249.43 | Recom | Buy | Prev Close | $200.49 | Price | $201.81 | Change | 0.66% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-21 | init | Canaccord Genuity | — → Buy | $262 |
| 2026-04-10 | main | Guggenheim | Buy → Buy | $249 |
| 2026-04-08 | main | Cantor Fitzgerald | Overweight → Overweight | $240 |
| 2026-02-25 | init | RBC Capital | — → Outperform | $260 |
| 2026-02-20 | init | Barclays | — → Overweight | $275 |
| 2026-02-18 | main | Piper Sandler | Overweight → Overweight | $299 |
| 2026-02-17 | main | Freedom Broker | Buy → Buy | $260 |
| 2026-02-05 | main | UBS | Neutral → Neutral | $230 |
| 2026-02-05 | main | Evercore ISI Group | Outperform → Outperform | $228 |
| 2026-02-05 | main | Morgan Stanley | Overweight → Overweight | $270 |
| 2026-01-27 | main | Citigroup | Neutral → Neutral | $230 |
| 2026-01-08 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-12-12 | main | Morgan Stanley | Overweight → Overweight | $269 |
| 2025-12-10 | up | HSBC | Hold → Buy | $265 |
| 2025-11-12 | main | Freedom Broker | Buy → Buy | $245 |
| 2025-11-07 | main | UBS | Neutral → Neutral | $220 |
| 2025-11-05 | reit | Piper Sandler | Overweight → Overweight | $289 |
| 2025-11-03 | main | Citigroup | Neutral → Neutral | $235 |
| 2025-11-03 | main | JP Morgan | Overweight → Overweight | $260 |
| 2025-10-20 | main | Guggenheim | Buy → Buy | $242 |
- AbbVie (ABBV): The Best Stock to Buy on a Pullback - Yahoo Finance hu, 23 Apr 2026 06
- Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4 - StockStory hu, 23 Apr 2026 09
- AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement - MEXC Wed, 22 Apr 2026 19
- What’s Happening With AbbVie Stock? - Trefis hu, 19 Mar 2026 07
- 734 jobs, 185 acres: AbbVie picks Durham for $1.4B drug hub - Stock Titan Wed, 22 Apr 2026 16
- Why I Can’t Stop Buying AbbVie Stock - 24/7 Wall St. Mon, 20 Apr 2026 14
- ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading. - Earnings Volatility - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 09
- AbbVie announces new $1.4B manufacturing campus (ABBV:NYSE) - Seeking Alpha Wed, 22 Apr 2026 16
- Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends - The Motley Fool Fri, 27 Mar 2026 07
- Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Lofty P/E Premium - simplywall.st Wed, 22 Apr 2026 04
- AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance Mon, 06 Apr 2026 07
- Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now - The Motley Fool Mon, 23 Mar 2026 07
- AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street - Yahoo Finance Mon, 20 Apr 2026 05
- AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development - Yahoo Finance Singapore Wed, 22 Apr 2026 21
- AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Wed, 08 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
61,160.00
+8.57%
|
56,334.00
+3.71%
|
54,318.00
-6.44%
|
58,054.00
|
| Operating Revenue |
|
61,160.00
+8.57%
|
56,334.00
+3.71%
|
54,318.00
-6.44%
|
58,054.00
|
| Cost Of Revenue |
|
18,204.00
+7.69%
|
16,904.00
-17.20%
|
20,415.00
+17.23%
|
17,414.00
|
| Reconciled Cost Of Revenue |
|
18,204.00
+7.69%
|
16,904.00
-17.20%
|
20,415.00
+17.23%
|
17,414.00
|
| Gross Profit |
|
42,956.00
+8.94%
|
39,430.00
+16.30%
|
33,903.00
-16.58%
|
40,640.00
|
| Operating Expense |
|
22,865.00
-16.96%
|
27,536.00
+35.19%
|
20,368.00
-6.68%
|
21,826.00
|
| Research And Development |
|
9,096.00
-28.89%
|
12,791.00
+66.66%
|
7,675.00
+17.90%
|
6,510.00
|
| Selling General And Administration |
|
14,010.00
-5.03%
|
14,752.00
+14.61%
|
12,872.00
-15.65%
|
15,260.00
|
| Other Operating Expenses |
|
-241.00
-3342.86%
|
-7.00
+96.09%
|
-179.00
-419.64%
|
56.00
|
| Total Expenses |
|
41,069.00
-7.59%
|
44,440.00
+8.97%
|
40,783.00
+3.93%
|
39,240.00
|
| Operating Income |
|
20,091.00
+68.92%
|
11,894.00
-12.12%
|
13,535.00
-28.06%
|
18,814.00
|
| Total Operating Income As Reported |
|
15,075.00
+64.99%
|
9,137.00
-28.38%
|
12,757.00
-29.59%
|
18,117.00
|
| EBITDA |
|
17,629.00
+18.24%
|
14,910.00
-13.17%
|
17,172.00
-28.97%
|
24,174.00
|
| Normalized EBITDA |
|
22,703.00
+28.35%
|
17,688.00
-2.25%
|
18,096.00
-27.67%
|
25,019.00
|
| Reconciled Depreciation |
|
8,139.00
-2.95%
|
8,386.00
-3.59%
|
8,698.00
+2.73%
|
8,467.00
|
| EBIT |
|
9,490.00
+45.46%
|
6,524.00
-23.01%
|
8,474.00
-46.05%
|
15,707.00
|
| Total Unusual Items |
|
-5,074.00
-82.65%
|
-2,778.00
-200.65%
|
-924.00
-9.35%
|
-845.00
|
| Total Unusual Items Excluding Goodwill |
|
-5,074.00
-82.65%
|
-2,778.00
-200.65%
|
-924.00
-9.35%
|
-845.00
|
| Special Income Charges |
|
-5,016.00
-81.94%
|
-2,757.00
-254.37%
|
-778.00
-11.62%
|
-697.00
|
| Other Special Charges |
|
5,016.00
+81.94%
|
2,757.00
+254.37%
|
778.00
+11.62%
|
697.00
|
| Net Income |
|
4,226.00
-1.22%
|
4,278.00
-12.03%
|
4,863.00
-58.91%
|
11,836.00
|
| Pretax Income |
|
6,597.00
+77.53%
|
3,716.00
-40.54%
|
6,250.00
-53.62%
|
13,477.00
|
| Net Non Operating Interest Income Expense |
|
-2,627.00
-21.62%
|
-2,160.00
-28.27%
|
-1,684.00
+17.61%
|
-2,044.00
|
| Interest Expense Non Operating |
|
2,893.00
+3.03%
|
2,808.00
+26.26%
|
2,224.00
-0.27%
|
2,230.00
|
| Net Interest Income |
|
-2,627.00
-21.62%
|
-2,160.00
-28.27%
|
-1,684.00
+17.61%
|
-2,044.00
|
| Interest Expense |
|
2,893.00
+3.03%
|
2,808.00
+26.26%
|
2,224.00
-0.27%
|
2,230.00
|
| Interest Income Non Operating |
|
266.00
-58.95%
|
648.00
+20.00%
|
540.00
+190.32%
|
186.00
|
| Interest Income |
|
266.00
-58.95%
|
648.00
+20.00%
|
540.00
+190.32%
|
186.00
|
| Other Income Expense |
|
-10,867.00
-80.57%
|
-6,018.00
-7.45%
|
-5,601.00
-70.09%
|
-3,293.00
|
| Other Non Operating Income Expenses |
|
-5,793.00
-78.80%
|
-3,240.00
+30.72%
|
-4,677.00
-91.05%
|
-2,448.00
|
| Gain On Sale Of Security |
|
-58.00
-176.19%
|
-21.00
+85.62%
|
-146.00
+1.35%
|
-148.00
|
| Tax Provision |
|
2,364.00
+514.74%
|
-570.00
-141.39%
|
1,377.00
-15.63%
|
1,632.00
|
| Tax Rate For Calcs |
|
0.00
+70.64%
|
0.00
-4.55%
|
0.00
+81.82%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1,818.24
-211.67%
|
-583.38
-186.98%
|
-203.28
-98.82%
|
-102.25
|
| Net Income Including Noncontrolling Interests |
|
4,233.00
-1.24%
|
4,286.00
-12.05%
|
4,873.00
-58.86%
|
11,845.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
4,226.00
-1.22%
|
4,278.00
-12.03%
|
4,863.00
-58.91%
|
11,836.00
|
| Net Income From Continuing And Discontinued Operation |
|
4,226.00
-1.22%
|
4,278.00
-12.03%
|
4,863.00
-58.91%
|
11,836.00
|
| Net Income Continuous Operations |
|
4,233.00
-1.24%
|
4,286.00
-12.05%
|
4,873.00
-58.86%
|
11,845.00
|
| Minority Interests |
|
-7.00
+12.50%
|
-8.00
+20.00%
|
-10.00
-11.11%
|
-9.00
|
| Normalized Income |
|
7,481.76
+15.59%
|
6,472.62
+15.92%
|
5,583.72
-55.61%
|
12,578.75
|
| Net Income Common Stockholders |
|
4,186.00
-1.23%
|
4,238.00
-12.07%
|
4,820.00
-59.09%
|
11,782.00
|
| Otherunder Preferred Stock Dividend |
|
40.00
+0.00%
|
40.00
-6.98%
|
43.00
-20.37%
|
54.00
|
| Diluted EPS |
|
2.37
-0.84%
|
2.39
-12.13%
|
2.72
-58.97%
|
6.63
|
| Basic EPS |
|
2.37
-2.21%
|
2.42
-12.00%
|
2.75
-58.84%
|
6.69
|
| Basic Average Shares |
|
1,769.00
+0.21%
|
1,765.26
-0.04%
|
1,765.94
-0.18%
|
1,769.18
|
| Diluted Average Shares |
|
1,773.00
+0.00%
|
1,773.00
+0.00%
|
1,773.00
-0.28%
|
1,778.00
|
| Diluted NI Availto Com Stockholders |
|
4,186.00
-1.23%
|
4,238.00
-12.07%
|
4,820.00
-59.09%
|
11,782.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
133,960.00
-0.89%
|
135,161.00
+0.33%
|
134,711.00
-2.95%
|
138,805.00
|
| Current Assets |
|
29,062.00
+13.60%
|
25,582.00
-22.48%
|
33,002.00
+15.95%
|
28,463.00
|
| Cash Cash Equivalents And Short Term Investments |
|
5,257.00
-5.36%
|
5,555.00
-56.66%
|
12,816.00
+38.87%
|
9,229.00
|
| Cash And Cash Equivalents |
|
5,229.00
-5.34%
|
5,524.00
-56.89%
|
12,814.00
+39.27%
|
9,201.00
|
| Other Short Term Investments |
|
28.00
-9.68%
|
31.00
+1450.00%
|
2.00
-92.86%
|
28.00
|
| Receivables |
|
12,589.00
+15.29%
|
10,919.00
-2.12%
|
11,155.00
-0.88%
|
11,254.00
|
| Accounts Receivable |
|
12,589.00
+15.29%
|
10,919.00
-2.12%
|
11,155.00
-0.88%
|
11,254.00
|
| Inventory |
|
4,951.00
+18.42%
|
4,181.00
+2.00%
|
4,099.00
+14.53%
|
3,579.00
|
| Raw Materials |
|
1,084.00
+2.55%
|
1,057.00
-3.91%
|
1,100.00
+10.00%
|
1,000.00
|
| Work In Process |
|
2,287.00
+17.22%
|
1,951.00
+18.75%
|
1,643.00
+15.95%
|
1,417.00
|
| Finished Goods |
|
1,580.00
+34.70%
|
1,173.00
-13.50%
|
1,356.00
+16.70%
|
1,162.00
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
6,265.00
+27.16%
|
4,927.00
-0.10%
|
4,932.00
+12.07%
|
4,401.00
|
| Total Non Current Assets |
|
104,898.00
-4.27%
|
109,579.00
+7.74%
|
101,709.00
-7.82%
|
110,342.00
|
| Net PPE |
|
5,628.00
+9.62%
|
5,134.00
+2.91%
|
4,989.00
+1.09%
|
4,935.00
|
| Gross PPE |
|
13,530.00
+10.30%
|
12,267.00
+5.43%
|
11,635.00
+5.91%
|
10,986.00
|
| Accumulated Depreciation |
|
-7,902.00
-10.78%
|
-7,133.00
-7.33%
|
-6,646.00
-9.83%
|
-6,051.00
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
287.00
+1.06%
|
284.00
-0.70%
|
286.00
+0.00%
|
286.00
|
| Buildings And Improvements |
|
3,057.00
+5.60%
|
2,895.00
+2.41%
|
2,827.00
+3.29%
|
2,737.00
|
| Machinery Furniture Equipment |
|
—
|
7,995.00
+7.33%
|
7,449.00
+4.81%
|
7,107.00
|
| Construction In Progress |
|
1,401.00
+28.18%
|
1,093.00
+1.86%
|
1,073.00
+25.35%
|
856.00
|
| Other Properties |
|
8,785.00
+9.88%
|
7,995.00
+7.33%
|
7,449.00
|
—
|
| Goodwill And Other Intangible Assets |
|
88,281.00
-7.10%
|
95,024.00
+8.10%
|
87,903.00
-11.74%
|
99,595.00
|
| Goodwill |
|
35,640.00
+1.96%
|
34,956.00
+8.25%
|
32,293.00
+0.43%
|
32,156.00
|
| Other Intangible Assets |
|
52,641.00
-12.36%
|
60,068.00
+8.02%
|
55,610.00
-17.54%
|
67,439.00
|
| Investments And Advances |
|
268.00
-3.94%
|
279.00
-8.22%
|
304.00
+26.14%
|
241.00
|
| Other Non Current Assets |
|
10,721.00
+17.27%
|
9,142.00
+7.39%
|
8,513.00
+52.81%
|
5,571.00
|
| Total Liabilities Net Minority Interest |
|
137,188.00
+4.09%
|
131,797.00
+6.02%
|
124,314.00
+2.30%
|
121,518.00
|
| Current Liabilities |
|
43,289.00
+11.72%
|
38,749.00
+2.40%
|
37,841.00
+28.11%
|
29,538.00
|
| Payables And Accrued Expenses |
|
34,734.00
+8.73%
|
31,945.00
+4.23%
|
30,650.00
+20.66%
|
25,402.00
|
| Payables |
|
6,691.00
+13.77%
|
5,881.00
-9.12%
|
6,471.00
+15.27%
|
5,614.00
|
| Accounts Payable |
|
3,592.00
+21.97%
|
2,945.00
-20.15%
|
3,688.00
+25.70%
|
2,934.00
|
| Dividends Payable |
|
3,099.00
+5.55%
|
2,936.00
+5.50%
|
2,783.00
+3.84%
|
2,680.00
|
| Current Accrued Expenses |
|
28,043.00
+7.59%
|
26,064.00
+7.80%
|
24,179.00
+22.19%
|
19,788.00
|
| Employee Benefits |
|
1,410.00
+14.26%
|
1,234.00
-19.77%
|
1,538.00
-6.11%
|
1,638.00
|
| Current Debt And Capital Lease Obligation |
|
8,555.00
+25.73%
|
6,804.00
-5.38%
|
7,191.00
+73.86%
|
4,136.00
|
| Current Debt |
|
8,555.00
+25.73%
|
6,804.00
-5.38%
|
7,191.00
+73.86%
|
4,136.00
|
| Current Deferred Liabilities |
|
—
|
14,304.00
+4.97%
|
13,627.00
+27.15%
|
10,717.00
|
| Current Deferred Revenue |
|
—
|
14,304.00
+4.97%
|
13,627.00
+27.15%
|
10,717.00
|
| Total Non Current Liabilities Net Minority Interest |
|
93,899.00
+0.91%
|
93,048.00
+7.60%
|
86,473.00
-5.99%
|
91,980.00
|
| Long Term Debt And Capital Lease Obligation |
|
58,941.00
-2.32%
|
60,340.00
+15.61%
|
52,194.00
-11.74%
|
59,135.00
|
| Long Term Debt |
|
58,941.00
-2.32%
|
60,340.00
+15.61%
|
52,194.00
-11.74%
|
59,135.00
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
1,410.00
+14.26%
|
1,234.00
-19.77%
|
1,538.00
-6.11%
|
1,638.00
|
| Tradeand Other Payables Non Current |
|
364.00
-71.13%
|
1,261.00
-42.21%
|
2,182.00
-26.90%
|
2,985.00
|
| Non Current Deferred Liabilities |
|
2,389.00
-7.37%
|
2,579.00
+32.12%
|
1,952.00
-10.87%
|
2,190.00
|
| Non Current Deferred Taxes Liabilities |
|
2,389.00
-7.37%
|
2,579.00
+32.12%
|
1,952.00
-10.87%
|
2,190.00
|
| Other Non Current Liabilities |
|
30,795.00
+11.44%
|
27,634.00
-3.40%
|
28,607.00
+9.89%
|
26,032.00
|
| Stockholders Equity |
|
-3,270.00
-198.35%
|
3,325.00
-67.91%
|
10,360.00
-39.96%
|
17,254.00
|
| Common Stock Equity |
|
-3,270.00
-198.35%
|
3,325.00
-67.91%
|
10,360.00
-39.96%
|
17,254.00
|
| Capital Stock |
|
18.00
+0.00%
|
18.00
+0.00%
|
18.00
+0.00%
|
18.00
|
| Common Stock |
|
18.00
+0.00%
|
18.00
+0.00%
|
18.00
+0.00%
|
18.00
|
| Share Issued |
|
1,838.68
+0.39%
|
1,831.59
+0.47%
|
1,823.05
+0.51%
|
1,813.77
|
| Ordinary Shares Number |
|
1,767.88
+0.15%
|
1,765.26
-0.04%
|
1,765.94
-0.18%
|
1,769.18
|
| Treasury Shares Number |
|
70.80
+6.73%
|
66.34
+16.17%
|
57.11
+28.07%
|
44.59
|
| Additional Paid In Capital |
|
22,495.00
+5.45%
|
21,333.00
+5.71%
|
20,180.00
+4.86%
|
19,245.00
|
| Retained Earnings |
|
-15,493.00
-96.11%
|
-7,900.00
-690.00%
|
-1,000.00
-120.90%
|
4,784.00
|
| Gains Losses Not Affecting Retained Earnings |
|
-1,144.00
+40.57%
|
-1,925.00
+16.49%
|
-2,305.00
-4.82%
|
-2,199.00
|
| Treasury Stock |
|
9,146.00
+11.52%
|
8,201.00
+25.53%
|
6,533.00
+42.21%
|
4,594.00
|
| Minority Interest |
|
42.00
+7.69%
|
39.00
+5.41%
|
37.00
+12.12%
|
33.00
|
| Other Equity Adjustments |
|
-1,144.00
+40.57%
|
-1,925.00
+16.49%
|
-2,305.00
-4.82%
|
-2,199.00
|
| Total Equity Gross Minority Interest |
|
-3,228.00
-195.96%
|
3,364.00
-67.64%
|
10,397.00
-39.86%
|
17,287.00
|
| Total Capitalization |
|
55,671.00
-12.56%
|
63,665.00
+1.78%
|
62,554.00
-18.11%
|
76,389.00
|
| Working Capital |
|
-14,227.00
-8.05%
|
-13,167.00
-172.10%
|
-4,839.00
-350.14%
|
-1,075.00
|
| Invested Capital |
|
64,226.00
-8.86%
|
70,469.00
+1.04%
|
69,745.00
-13.39%
|
80,525.00
|
| Total Debt |
|
67,496.00
+0.52%
|
67,144.00
+13.07%
|
59,385.00
-6.14%
|
63,271.00
|
| Net Debt |
|
62,267.00
+1.05%
|
61,620.00
+32.31%
|
46,571.00
-13.87%
|
54,070.00
|
| Net Tangible Assets |
|
-91,551.00
+0.16%
|
-91,699.00
-18.26%
|
-77,543.00
+5.83%
|
-82,341.00
|
| Tangible Book Value |
|
-91,551.00
+0.16%
|
-91,699.00
-18.26%
|
-77,543.00
+5.83%
|
-82,341.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
19,030.00
+1.19%
|
18,806.00
-17.66%
|
22,839.00
-8.44%
|
24,943.00
|
| Cash Flow From Continuing Operating Activities |
|
19,030.00
+1.19%
|
18,806.00
-17.66%
|
22,839.00
-8.44%
|
24,943.00
|
| Net Income From Continuing Operations |
|
4,233.00
-1.24%
|
4,286.00
-12.05%
|
4,873.00
-58.86%
|
11,845.00
|
| Depreciation Amortization Depletion |
|
8,139.00
-2.95%
|
8,386.00
-3.59%
|
8,698.00
+2.73%
|
8,467.00
|
| Depreciation |
|
762.00
-0.26%
|
764.00
+1.60%
|
752.00
-3.34%
|
778.00
|
| Amortization Cash Flow |
|
7,377.00
-3.21%
|
7,622.00
-4.08%
|
7,946.00
+3.34%
|
7,689.00
|
| Depreciation And Amortization |
|
8,139.00
-2.95%
|
8,386.00
-3.59%
|
8,698.00
+2.73%
|
8,467.00
|
| Amortization Of Intangibles |
|
7,377.00
-3.21%
|
7,622.00
-4.08%
|
7,946.00
+3.34%
|
7,689.00
|
| Other Non Cash Items |
|
8,643.00
+93.36%
|
4,470.00
-7.09%
|
4,811.00
+53.02%
|
3,144.00
|
| Stock Based Compensation |
|
955.00
+4.83%
|
911.00
+21.95%
|
747.00
+11.33%
|
671.00
|
| Provisionand Write Offof Assets |
|
-933.00
-283.66%
|
508.00
+214.67%
|
-443.00
-119.75%
|
2,243.00
|
| Asset Impairment Charge |
|
847.00
-81.08%
|
4,476.00
+5.84%
|
4,229.00
+449.22%
|
770.00
|
| Deferred Tax |
|
-492.00
+66.05%
|
-1,449.00
+49.84%
|
-2,889.00
-49.61%
|
-1,931.00
|
| Deferred Income Tax |
|
-492.00
+66.05%
|
-1,449.00
+49.84%
|
-2,889.00
-49.61%
|
-1,931.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-172.00
|
| Change In Working Capital |
|
-2,362.00
+15.10%
|
-2,782.00
-198.90%
|
2,813.00
+3092.55%
|
-94.00
|
| Change In Receivables |
|
-1,490.00
-819.81%
|
207.00
+213.64%
|
66.00
+104.54%
|
-1,455.00
|
| Changes In Account Receivables |
|
-1,490.00
-819.81%
|
207.00
+213.64%
|
66.00
+104.54%
|
-1,455.00
|
| Change In Inventory |
|
-234.00
+26.65%
|
-319.00
+23.50%
|
-417.00
+39.21%
|
-686.00
|
| Change In Prepaid Assets |
|
-827.00
-329.09%
|
361.00
+292.02%
|
-188.00
+28.79%
|
-264.00
|
| Change In Payables And Accrued Expense |
|
951.00
+437.29%
|
177.00
-95.39%
|
3,840.00
+117.07%
|
1,769.00
|
| Change In Payable |
|
951.00
+437.29%
|
177.00
-95.39%
|
3,840.00
+117.07%
|
1,769.00
|
| Change In Account Payable |
|
951.00
+437.29%
|
177.00
-95.39%
|
3,840.00
+117.07%
|
1,769.00
|
| Change In Other Working Capital |
|
-762.00
+76.25%
|
-3,208.00
-557.38%
|
-488.00
-190.04%
|
542.00
|
| Investing Cash Flow |
|
-6,643.00
+68.09%
|
-20,820.00
-936.34%
|
-2,009.00
-222.47%
|
-623.00
|
| Cash Flow From Continuing Investing Activities |
|
-6,643.00
+68.09%
|
-20,820.00
-936.34%
|
-2,009.00
-222.47%
|
-623.00
|
| Net PPE Purchase And Sale |
|
-1,214.00
-24.64%
|
-974.00
-25.35%
|
-777.00
-11.80%
|
-695.00
|
| Purchase Of PPE |
|
-1,214.00
-24.64%
|
-974.00
-25.35%
|
-777.00
-11.80%
|
-695.00
|
| Capital Expenditure |
|
-1,214.00
-24.64%
|
-974.00
-25.35%
|
-777.00
-11.80%
|
-695.00
|
| Net Investment Purchase And Sale |
|
41.00
-91.49%
|
482.00
+2290.91%
|
-22.00
-123.91%
|
92.00
|
| Purchase Of Investment |
|
-35.00
+52.05%
|
-73.00
+5.19%
|
-77.00
+94.65%
|
-1,438.00
|
| Sale Of Investment |
|
76.00
-86.31%
|
555.00
+909.09%
|
55.00
-96.41%
|
1,530.00
|
| Net Business Purchase And Sale |
|
-5,441.00
+73.48%
|
-20,517.00
-1577.60%
|
-1,223.00
-54.03%
|
-794.00
|
| Purchase Of Business |
|
-5,441.00
+73.48%
|
-20,517.00
-1577.60%
|
-1,223.00
-54.03%
|
-794.00
|
| Gain Loss On Sale Of Business |
|
—
|
0.00
|
0.00
+100.00%
|
-172.00
|
| Net Other Investing Changes |
|
-29.00
-115.34%
|
189.00
+1353.85%
|
13.00
-98.32%
|
774.00
|
| Financing Cash Flow |
|
-12,724.00
-144.18%
|
-5,211.00
+69.74%
|
-17,222.00
+30.56%
|
-24,803.00
|
| Cash Flow From Continuing Financing Activities |
|
-12,724.00
-144.18%
|
-5,211.00
+69.74%
|
-17,222.00
+30.56%
|
-24,803.00
|
| Net Issuance Payments Of Debt |
|
-304.00
-104.14%
|
7,350.00
+277.15%
|
-4,149.00
+66.63%
|
-12,433.00
|
| Issuance Of Debt |
|
9,291.00
-57.71%
|
21,971.00
|
0.00
-100.00%
|
2,000.00
|
| Repayment Of Debt |
|
-9,595.00
+34.38%
|
-14,621.00
-252.40%
|
-4,149.00
+71.25%
|
-14,433.00
|
| Long Term Debt Issuance |
|
3,994.00
-76.45%
|
16,963.00
|
0.00
-100.00%
|
2,000.00
|
| Long Term Debt Payments |
|
-6,797.00
+29.29%
|
-9,613.00
-131.69%
|
-4,149.00
+71.25%
|
-14,433.00
|
| Net Long Term Debt Issuance |
|
-2,803.00
-138.14%
|
7,350.00
+277.15%
|
-4,149.00
+66.63%
|
-12,433.00
|
| Short Term Debt Issuance |
|
5,297.00
+5.77%
|
5,008.00
|
0.00
|
0.00
|
| Short Term Debt Payments |
|
-2,798.00
+44.13%
|
-5,008.00
|
0.00
|
0.00
|
| Net Short Term Debt Issuance |
|
2,499.00
|
0.00
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
-980.00
+42.62%
|
-1,708.00
+13.39%
|
-1,972.00
-32.62%
|
-1,487.00
|
| Common Stock Payments |
|
-980.00
+42.62%
|
-1,708.00
+13.39%
|
-1,972.00
-32.62%
|
-1,487.00
|
| Common Stock Dividend Paid |
|
-11,657.00
-5.73%
|
-11,025.00
-4.61%
|
-10,539.00
-4.94%
|
-10,043.00
|
| Cash Dividends Paid |
|
-11,657.00
-5.73%
|
-11,025.00
-4.61%
|
-10,539.00
-4.94%
|
-10,043.00
|
| Repurchase Of Capital Stock |
|
-980.00
+42.62%
|
-1,708.00
+13.39%
|
-1,972.00
-32.62%
|
-1,487.00
|
| Proceeds From Stock Option Exercised |
|
172.00
-19.63%
|
214.00
+18.89%
|
180.00
-31.30%
|
262.00
|
| Net Other Financing Charges |
|
45.00
+207.14%
|
-42.00
+94.34%
|
-742.00
+32.67%
|
-1,102.00
|
| Changes In Cash |
|
-337.00
+95.34%
|
-7,225.00
-300.25%
|
3,608.00
+847.00%
|
-483.00
|
| Effect Of Exchange Rate Changes |
|
42.00
+164.62%
|
-65.00
-1400.00%
|
5.00
+108.06%
|
-62.00
|
| Beginning Cash Position |
|
5,524.00
-56.89%
|
12,814.00
+39.27%
|
9,201.00
-5.59%
|
9,746.00
|
| End Cash Position |
|
5,229.00
-5.34%
|
5,524.00
-56.89%
|
12,814.00
+39.27%
|
9,201.00
|
| Free Cash Flow |
|
17,816.00
-0.09%
|
17,832.00
-19.17%
|
22,062.00
-9.02%
|
24,248.00
|
| Interest Paid Supplemental Data |
|
3,002.00
+6.79%
|
2,811.00
+13.85%
|
2,469.00
-3.02%
|
2,546.00
|
| Income Tax Paid Supplemental Data |
|
3,626.00
-10.78%
|
4,064.00
-13.57%
|
4,702.00
+57.36%
|
2,988.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-03 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-03-06 View
- 42026-03-06 View
- 8-K2026-03-04 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-02-27 View
- 8-K2026-02-26 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|